Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial.
Nysom K, Kilburn LB, Leary SES, Landi DB, de Vos-Kerkhof E, Perreault S, Witt O, Ziegler DS, Hernáiz Driever P, Franson AT, Baxter PA, Whipple NS, Kline C, Segal D, Jabado N, Bailey S, McCowage G, Hansford JR, Khuong-Quang DA, Gottardo NG, Hassall T, Han JW, Yalon Oren M, Chi SN, Qiu J, Da Costa D, Govinda Raju S, Manley P, Hargrave D. Nysom K, et al. Among authors: franson at. Neuro Oncol. 2024 Dec 19:noae274. doi: 10.1093/neuonc/noae274. Online ahead of print. Neuro Oncol. 2024. PMID: 39700439
Clinical characteristics and outcome of central nervous system tumors harboring NTRK gene fusions.
Lamoureux AA, Fisher MJ, Lemelle L, Pfaff E, Amir-Yazdani P, Kramm C, De Wilde B, Kazanowska B, Hutter C, Pfister SM, Sturm D, Jones DTW, Orbach D, Pierron G, Raskin S, Drilon A, Diamond EL, Harada G, Zapotocky M, Zamecnik J, Krskova L, Ellezam B, Weil AG, Venne D, Barritault M, Leblond P, Coltin H, Hammad R, Tabori U, Hawkins C, Hansford JR, Meyran D, Erker C, McFadden K, Sato M, Gottardo NG, Dholaria H, Nørøxe DS, Goto H, Ziegler DS, Lin FY, Parsons DW, Lindsay H, Wong TT, Liu YL, Wu KS, Franson AT, Hwang E, Aguilar-Bonilla A, Cheng S, Cacciotti C, Massimino M, Schiavello E, Wood P, Hoffman LM, Cappellano A, Lassaletta A, Van Damme A, Llort A, Gerber NU, Spalato Ceruso M, Bendel AE, Skrypek M, Hamideh D, Mushtaq N, Walter A, Jabado N, Alsahlawi A, Farmer JP, Coleman C, Mueller S, Mazewski C, Aguilera D, Robison NJ, O'Halloran K, Abbou S, Berlanga P, Geoerger B, Øra I, Moertel CL, Razis ED, Vernadou A, Ducray F, Bronnimann C, Seizeur R, Clarke M, Resnick AC, Alves M, Jones C, Doz F, Laetsch TW, Perreault S. Lamoureux AA, et al. Among authors: franson at. Clin Cancer Res. 2024 Dec 3. doi: 10.1158/1078-0432.CCR-24-0581. Online ahead of print. Clin Cancer Res. 2024. PMID: 39625867
Retrospective Comparison of Targeted Anticancer Drugs Predicted by the CNS-TAP Tool Versus Those Selected by a Molecularly Driven Tumor Board in Children With DIPG.
Roberts HJ, Ravi K, Marini BL, Schepers A, Kline C, Kilburn L, Prados M, Byron SA, Sturza J, Mueller S, Koschmann C, Franson AT. Roberts HJ, et al. Among authors: franson at. J Pediatr Hematol Oncol. 2024 Nov 6. doi: 10.1097/MPH.0000000000002964. Online ahead of print. J Pediatr Hematol Oncol. 2024. PMID: 39527919
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.
Moertel CL, Hirbe AC, Shuhaiber HH, Bielamowicz K, Sidhu A, Viskochil D, Weber MD, Lokku A, Smith LM, Foreman NK, Hajjar FM, McNall-Knapp RY, Weintraub L, Antony R, Franson AT, Meade J, Schiff D, Walbert T, Ambady P, Bota DA, Campen CJ, Kaur G, Klesse LJ, Maraka S, Moots PL, Nevel K, Bornhorst M, Aguilar-Bonilla A, Chagnon S, Dalvi N, Gupta P, Khatib Z, Metrock LK, Nghiemphu PL, Roberts RD, Robison NJ, Sadighi Z, Stapleton S, Babovic-Vuksanovic D, Gershon TR; ReNeu Trial Investigators; ReNeu Study Investigators. Moertel CL, et al. Among authors: franson at. J Clin Oncol. 2024 Nov 8:JCO2401034. doi: 10.1200/JCO.24.01034. Online ahead of print. J Clin Oncol. 2024. PMID: 39514826
Long-Term Tumor Stability After First-Line Treatment With Larotrectinib in an Infant With NTRK2 Fusion-Positive High-Grade Glioma.
Simoneau J, Robertson P, Muraszko K, Maher CO, Garton H, Calvert R, Koschmann C, Upadhyaya SA, Mody R, Brown N, Kumar-Sinha C, Parmar H, Camelo-Piragua S, Franson AT. Simoneau J, et al. Among authors: franson at. J Natl Compr Canc Netw. 2024 Sep;22(7):e247045. doi: 10.6004/jnccn.2024.7045. J Natl Compr Canc Netw. 2024. PMID: 39236755
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Kilburn LB, Khuong-Quang DA, Hansford JR, Landi D, van der Lugt J, Leary SES, Driever PH, Bailey S, Perreault S, McCowage G, Waanders AJ, Ziegler DS, Witt O, Baxter PA, Kang HJ, Hassall TE, Han JW, Hargrave D, Franson AT, Yalon Oren M, Toledano H, Larouche V, Kline C, Abdelbaki MS, Jabado N, Gottardo NG, Gerber NU, Whipple NS, Segal D, Chi SN, Oren L, Tan EEK, Mueller S, Cornelio I, McLeod L, Zhao X, Walter A, Da Costa D, Manley P, Blackman SC, Packer RJ, Nysom K. Kilburn LB, et al. Among authors: franson at. Nat Med. 2024 May;30(5):1500. doi: 10.1038/s41591-024-02910-1. Nat Med. 2024. PMID: 38467878 Free PMC article. No abstract available.
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.
Hogarty MD, Ziegler DS, Franson A, Chi YY, Tsao-Wei D, Liu K, Vemu R, Gerner EW, Bruckheimer E, Shamirian A, Hasenauer B, Balis FM, Groshen S, Norris MD, Haber M, Park JR, Matthay KK, Marachelian A. Hogarty MD, et al. Among authors: franson a. Br J Cancer. 2024 Mar;130(5):788-797. doi: 10.1038/s41416-023-02525-2. Epub 2024 Jan 10. Br J Cancer. 2024. PMID: 38200233 Free PMC article. Clinical Trial.
34 results